News
Gilead will donate 1.5M doses of experimental coronavirus drug to patients
Gilead Sciences said it is donating 1.5 million doses of its experimental anti-coronavirus drug remdesivir, which could potentially treat 140,000 severely ill patients.
The doses are available for compassionate use, expanded access and clinical trials and will be donated for...
News
BiologIC’s pioneering digital hardware architectures for synthetic biology accelerated by the Stratasys J826 3D printer
BiologIC Technologies, a pioneer in powerful digital architectures for radically disruptive automation hardware in synthetic biology, has announced today that it is accelerating development using the recently launched J826 3D printer from Stratasys, a global leader in additive manufacturing...
News
PBOA Members Support Efforts Against COVID-19
The Pharma & Biopharma Outsourcing Association (PBOA), a trade group that represents Contract Manufacturing Organizations (CMOs) and other service providers in the bio/pharmaceutical sector, reports that many of its member companies are actively involved in helping their clients develop...
News
Mount Sinai Uses Remote Patient Monitoring to Rapidly Respond to COVID-19
Mount Sinai Health System is helping health care providers to care for COVID-19 patients who are recovering at home. With the platform, providers can monitor the patients’ symptoms and adjust care as necessary, including sending the patient to the...
News
GSK allies with Innovax for COVID-19 vaccine R&D project
GlaxoSmithKline has teamed up with Xiamen Innovax Biotech to evaluate a vaccine against the novel coronavirus behind the COVID-19 pandemic. The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based...
Clinical Trials
Ergomed Announces Provision of Clinical Research Services for Second COVID-19
Ergomed plc , a company focused on providing specialised services to the pharmaceutical industry, announces it is providing support for a clinical development programme for namilumab, a monoclonal antibody therapy targeting granulocyte-macrophage colony stimulating factor (GM-CSF), for the treatment...
News
Gilead ramps up production of experimental Covid-19 treatment amid criticism over access
Gilead Sciences has been ramping up production of its experimental remdesivir treatment that is being tested to combat the novel coronavirus.
The drug maker now has 1.5 million individual dosages that could be used for more than 140,000 patients and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read